| 05th week of 2011 patent applcation highlights part 38 |
| Patent application number | Title | Published |
|---|
| 20110027312 | CHIMERIC PORCINE CIRCOVIRUS PCV2Gen-1Rep AND USES THEREOF - The present invention relates to a novel chimeric nucleic acid molecule of porcine circovirus (PCV2Gen-1Rep) that embraces a nucleic acid molecule encoding porcine circovirus type 2 (PCV2) which contains a nucleic acid sequence encoding a Rep protein of porcine circovirus type 1 (PCV1), particularly wherein the nucleic acid sequence encoding the Rep protein of PCV1 GO is an open reading frame (ORF) gene and, more particularly, wherein the ORF Rep gene is ORF1. A highly desirable chimeric nucleic acid molecule is constructed by replacing the ORF1 Rep gene of PCV2 by the ORF1 Rep gene of PCV1. The invention also encompasses the biologically functional plasmid or viral vector containing the unique chimeric nucleic acid molecules, suitable host cells transfected by the plasmid or vector, infectious chimeric porcine circoviruses that are produced by the suitable host cells, the process for the production of an immunogenic polypeptide product making use of the new chimera, viral vaccines that protect a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, methods of protecting a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, methods of preparing the unique chimera of PCV2Gen-1Rep and the like. This invention further includes a new method for improving the replication and titer of PCV2 in a cell culture. | 2011-02-03 |
| 20110027313 | VIRAL RECOMBINEERING AND USES THEREOF - The invention uses recombinant technology to create infectious molecular clones that capture the sequence diversity of viral genes found in natural populations of mixed genotype viruses, such as arises during HIV infections and many other viral diseases. The invention captures the sequence diversity of different genes in these “quasi-species” populations by recombining them into in a constant genetic “backbone” for each viral species by backcrossing PCR products derived from quasispecies gene variants into this backbone in an | 2011-02-03 |
| 20110027314 | Influenza Vaccines Containing Hemagglutinin and Matrix Proteins - An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2 OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins. | 2011-02-03 |
| 20110027315 | PROTEIN CAGES AND THEIR USES - The present disclosure provides compositions comprising a protein cage and methods for using the protein cage compositions to induce an immune protection response, or to prevent or ameliorate a viral or a bacterial infection. | 2011-02-03 |
| 20110027316 | BLUETONGUE VIRUS VACCINE AND IMMUNOGENIC COMPOSITIONS, METHODS OF USE AND METHODS OF PRODUCING SAME - Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus. | 2011-02-03 |
| 20110027317 | Production of poliovirus at high titers for vaccine production - Provided is a process for the production of poliovirus, comprising the steps of: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×10 | 2011-02-03 |
| 20110027318 | NUCLEOTIDE VECTOR, COMPOSITION CONTAINING SUCH VECTOR, AND VACCINE FOR IMMUNIZATION AGAINST HEPATITIS - Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers. | 2011-02-03 |
| 20110027319 | METHODS OF ELICITING OR BOOSTING A CELLULAR IMMUNE RESPONSE - Site-specific | 2011-02-03 |
| 20110027321 | Chlamydia Vaccine Comprising HtrA Polypeptides - The present invention provides vaccine compositions useful in prevention and treatment of | 2011-02-03 |
| 20110027322 | TUMOR VACCINE, A METHOD FOR PRODUCING A TUMOR VACCINE AND A METHOD FOR CARRYING OUT ANTITUMOR IMMUNOTHERAPY - The group of inventions relates to medical engineering, in particular to the immunotherapy of cancer patients. The inventive tumor vaccine based on surface tumor antigens comprises a mixture of surface tumor antigens. The method for producing a tumor vaccine consists in cultivating tumor cells and in separating surface tumor antigens. The primary culture of living tumor cells, which is pre-washed of a growth medium, is exposed to a proteases action vital for cells and the thus released surface tumor antigens are separated. The primary culture of living tumor cells is repeatedly treated by proteases at intervals necessary for recovering the surface tumor antigens by means of cells. The surface tumor antigens are accumulated until a dose thereof, required for vaccination, is obtained, the composition of the thus obtained surface tumor antigens is tested. Trypsin can be used as protease. The method for carrying out antitumor immunotherapy consists in administrating the tumor vaccine in a patient body. The inventive group of inventions makes it possible to increase the effectiveness of treatment of oncological diseases by enhancing an antitumor immune response. | 2011-02-03 |
| 20110027323 | ADJUVANTS AND METHODS OF USE - Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed. Further provided are vaccine preparations comprising NKT cell agonist compounds. | 2011-02-03 |
| 20110027324 | O-DESMETHYL-VENLAFAXINE FOR TREATING MAJOR DEPRESSIVE DISORDER - The present invention provides methods for treating MDD. In general, the methods comprise administering to a patient in need thereof a daily dose of about 50 mg ODV or an equivalent amount of a pharmaceutically acceptable salt thereof. In certain embodiments, a patient in need of treatment is characterized by a primary diagnosis of MDD. In some embodiments, the dose is administered as a single daily dose. In one set of embodiments, the methods involve administering an oral dosage form comprising the succinate salt of ODV. | 2011-02-03 |
| 20110027325 | ORALLY-ADMINISTERED AGENT - An orally-administered agent according to the present invention comprises: a medicine-containing layer containing a medicine and having surfaces; collapse-controlling layers respectively provided on the surfaces of the medicine-containing layer; and gel-forming layers respectively provided on the collapse-controlling layers, wherein the gel-forming layers are swelled and gelatinized by absorbing water to form a gel. The collapse-controlling layers are constituted of a material containing a stomach-soluble material to be dissolved by being in contact with gastric juice. The orally-administered agent according to the present invention can be swallowed with ease and release the medicine in intended parts, in particular, the stomach of a living body. | 2011-02-03 |
| 20110027326 | External Composition for Skin - An external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols. | 2011-02-03 |
| 20110027327 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION - A cosmetic or pharmaceutical composition, to be applied topically is described, which has a hydrophilic outer phase, at least one cosmetic and/or pharmaceutical active ingredient and at least one carrier substance for the active ingredient. The carrier substance here forms such structures, which comprises at least two lamellar double membrane layers arranged one over another in the manner of a sandwich, wherein between adjacent double membrane layers, aligned parallel to each other, a layer of an inner phase is respectively arranged. The active ingredient is distributed in the double membrane layer and in the layer of the inner phase such that the layer of the inner phase contains the active ingredient in a concentration range between 2% by weight and 98% by weight and the double membrane layer contains the active ingredient in a concentration between 98% by weight and 2% by weight, respectively in relation to the total concentration of active ingredient, and the outer phase has no or almost no active ingredient. | 2011-02-03 |
| 20110027328 | Oral Care Articles and Methods - An oral care article in the form of a flexible porous dissolvable solid structure, comprising: from about 1% to about 70% surfactant; from about 10% to about 70% water soluble polymer, from about 0% to about 25% plasticizer; and wherein said article comprises an oral care component and has a density of from about 0.03 g/cm | 2011-02-03 |
| 20110027329 | Single-use, Disposable Strip For Application Of Topical Compositions - A topical treatment strip comprising a substrate having two surfaces with a topical composition carried thereupon. The treatment strip can be used to treat two surfaces of subject as such as both lips simultaneously. Methods include methods of manufacture and methods of use. | 2011-02-03 |
| 20110027330 | Tablet composition for the in-situ generation of chlorine dioxide for use in antimicrobial applications - A fast-acting solid composition in the form of a tablet that generates and releases a biocidal solution comprising at least chlorine dioxide with an enhanced weight percent yield of at least 20 wt % is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide comprising a chlorite donor that is coated with a non-hygroscopic material that enhances the environmental stability of the composition. | 2011-02-03 |
| 20110027331 | AN IMPLANTABLE DRUG DEPOT HAVING A REVERSIBLE PHASE TRANSITION MATERIAL FOR TREATMENT OF PAIN AND/OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided that utilize a reversible phase transition material of a drug depot. When heat, cold or another suitable form of energy, e.g., ultrasound energy is applied to the reversible phase transition material, the release of an analgesic and/or anti-inflammatory agent from a drug depot is increased. | 2011-02-03 |
| 20110027332 | PLIABLE MEDICAL DEVICE AND METHOD OF USE - A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of the body, it will hold its shape well, for an extended time. Because the lyophilized pliable medical device is porous, it adsorbs blood and other beneficial cells containing body fluids, such as bone marrow, contributing to its superior bone repair efficacy in comparison to an analogous putty that has not been lyophilized. In addition these lyophilized pliable medical devices are easier to terminally steam sterilize than the analogous putty because there is no moisture present to boil and “blow-out” of the containment device (syringe). The glycerin that is present in the formulation lends pliability but has a low vapor pressure. | 2011-02-03 |
| 20110027333 | STEM CELL-DERIVED RETIN RETINAL PIGMENT EPITHELIAL CELLS - The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells. | 2011-02-03 |
| 20110027334 | MULTILAYER MEDICAL DEVICES HAVING AN ENCAPSULATED EDGE AND METHODS THEREOF - The present disclosure describes a medical which includes a body defining a conduit. The body includes a multilayer wall having at least one edge. The wall including a core layer positioned between an inner layer and an outer layer, wherein at least one of the inner and outer layers encapsulates the core layer along the edge. | 2011-02-03 |
| 20110027335 | COATED MEDICAL DEVICES - An implantable medical device carries on at least part of its external surface a coating. The coating consists essentially of a terpolymer of vinyl pyrrolidone, acrylic acid and activated acrylic acid, and optionally a colouring agent. | 2011-02-03 |
| 20110027336 | COATINGS FOR IMPLANTABLE DEVICES COMPRISING POLYMERS OF LACTIC ACID AND METHODS FOR FABRICATING THE SAME - Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising polymers of lactic acid. | 2011-02-03 |
| 20110027337 | PROTEASE INHIBITOR - The present invention relates to a polypeptide exhibiting a protease inhibitory activity and uses of said polypeptide in methods for inhibiting, directly or indirectly, one or more proteases of the blood clotting cascade. The invention also relates to use of said polypeptide as a pharmaceutical e.g. for prophylactic or ameliorating treatment of blood clots. In addition the invention comprises methods for production of said polypeptide. | 2011-02-03 |
| 20110027338 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 2011-02-03 |
| 20110027339 | POROUS IMPLANTS AND STENTS AS CONTROLLED RELEASE DRUG DELIVERY CARRIERS - The common premise of synthetic implants in the restoration of diseased tissues and organs is to use inert and solid materials. Here, a porous titanium implant enables the delivery of microencapsulated bioactive cues. Control-released TGFβ1 promoted the proliferation and migration of human mesenchymal stem cells into porous implants in vitro. Upon 4-wk implantation in the rabbit humerus, control-released TGFβ1 from porous implants significantly increased BIC by 96% and bone ingrowth by 50% over placebos. Control-released 100 ng TGFβ1 induced equivalent BIC and bone ingrowth to adsorbed 1 μg TGFβ1, suggesting that controlled release is effective at 10-fold less drug dose than adsorption. Histomorphometry, SEM and μT showed that control-released TGFβ1 enhanced bone ingrowth in the implant's pores and surface. These findings suggest that solid prostheses can be transformed into porous implants to serve as drug delivery carriers, from which control-released bioactive cues augment host tissue integration. | 2011-02-03 |
| 20110027340 | IMPLANTABLE DRUG DEPOT FOR WEIGHT CONTROL - The present invention is directed to an implantable drug depot for weight control. The drug depot includes at least one biodegradeable polymer and at least one biologically active agent. Through the administration of an effective amount of the biologically active agent at or near a target site, one can control weight gain and/or reduce, prevent or treat obesity. When appropriate formulations are provided within biodegradable polymers, weight control or treatment can be conducted for at least five days and up to one hundred and thirty-five days. | 2011-02-03 |
| 20110027341 | DEVICE FOR IN SITU PRODUCTION AND TOPICAL ADMINISTRATION OF ALLICIN - The present invention relates to a drug delivery device that is useful for topical treatment of various infections such as skin and nail, or vaginal infections. More specifically, the invention provides a device for topical administration of allicin to an infection site, comprising either one solid carrier or two adjacent solid carriers, dry alliin and dry alliinase, wherein either a mixture of said dry alliin and dry alliinase is contained within said one solid carrier or dry alliin and dry alliinase are each separately contained within each one of said two adjacent solid carriers, whereby in contact with the infection site and a wetting agent, the alliinase acts on the alliin and allicin is produced in situ and administered to the infection site | 2011-02-03 |
| 20110027342 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY - The invention relates to compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and to methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. The enhanced bioavailability formulations may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease. | 2011-02-03 |
| 20110027343 | Animal Food Having Low Water Activity - A method of providing an animal food having an active. A Probiotic animal food having a low water activity that can be contained within a package having a low vapor transmission rate. The animal food can have a shelf life sufficient to deliver a target dose of Probiotic to an animal. The water activity of the animal food can be controlled. The activity level of the Probiotic can be controlled. | 2011-02-03 |
| 20110027344 | Alginate-Containing Wound Dressing, Method and Apparatus for Making the Same - Disclosed herein is a wound dressing. The wound dressing includes a first fiber layer and a second fiber layer stacked on and bound to the first fiber layer. The first fiber layer consists of a plurality of a first fiber that are made of an alginate wherein the first fibers are respectively bound with one another, and are substantially extended in parallel along a first direction. The second fiber layer consists of a plurality of a second fiber that are made of an alginate, wherein the second fibers are respectively bound with one another, and extend in parallel along a second direction that is not parallel to the first direction. The second layer is stacked on the first layer with the second fibers being bound with the first fibers. The first fibers and the second fibers respectively have a length such that the wound dressing has a breaking strength for at least 1.5 kg. | 2011-02-03 |
| 20110027345 | COMPOSITION CONTAINING ROTIGOTINE AND USE THEREOF AND TRANSDERMAL PATCH CONTAINING THE COMPOSITION - The present invention relates to a composition containing Rotigotine and the use thereof in the manufacture of a Rotigotine-containing transdermal patch, wherein said composition is based on a matrix mixture system formed from a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive, and polyvinylpyrrolidone which are present in a particular weight ratio, wherein (1) the acrylic pressure-sensitive adhesive is present in an amount of about 1-25% by weight in the matrix mixture system, (2) the silicone pressure-sensitive adhesive is present in an amount of about 65-98% by weight in the matrix mixture system, and (3) the polyvinylpyrrolidone is present in an amount of about 1-10% by weight in the matrix mixture system, and comprises 1-40% of Rotigotine on the basis of the total weight of the composition. The present invention further relates to an improved transdermal patch containing Rotigotine comprising said composition. Said patch has improved properties in the solubility, release and initial penetration level of Rotigotine. | 2011-02-03 |
| 20110027346 | Lyase Enzymes, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts. | 2011-02-03 |
| 20110027347 | POLYMERSOMES AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis and pharmacology of polymersomes containing one or more bioactive agents. The polymersome is generally derived from a polymer having the formula XY | 2011-02-03 |
| 20110027348 | COMPOSITION AND METHOD INHIBITING INFLAMMATION - Composition and method for preventing, treating or attenuating inflammatory diseases by way of inhibiting lipid peroxidation and subsequent elementary inflammation through ensuring the presence of the following biologically active ingredients in the PMRS of cells involved in inflammation: i) at least one killed probiotic and ii) at least one omega 3 FA and iii) vitamin E and iv) ubiquinone by introducing a composition comprising any of the missing ingredients. | 2011-02-03 |
| 20110027349 | POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM - A vaccine is provided wherein a polypeptide or combination of peptides from | 2011-02-03 |
| 20110027350 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS - A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety. | 2011-02-03 |
| 20110027351 | LIPOSOMAL FORMULATIONS COMPRISING AN AMPHIPATHIC WEAK BASE LIKE TEMPAMINE FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS - Provided is the use of an amphipathic weak base having defined characteristics for the preparation of a pharmaceutical formulation for the treatment or prevention of neurodegenerative conditions. The amphipathic weak base can be encapsulated in a liposome. Also provided are pharmaceutical formulations and methods of use thereof for the treatment or prevention of neurodegenerative conditions. A specific and amphipathic weak base is tempamine (TMN). Further, tempamine can be loaded in sterically stabilized liposomes (SSL-TMN). | 2011-02-03 |
| 20110027352 | COMPOUNDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to the use of a beta-adrenergic receptor agonist as active ingredient for the production of a medicament for use in the treatment of neuropathic pain, in particular neuropathic allodynia, in particular chronic neuropathic allodynia, and more generally for the production of medicaments for relieving pain. The principal field of application of the present invention is the biomedical field, and more specifically the therapeutics field. The present invention aims in particular to provide a medicament which can be used as a substitute for the antidepressants currently used to treat pain. It finds a use in the human and veterinary clinical field. | 2011-02-03 |
| 20110027353 | Therapeutic Delivery System - Therapeutic delivery systems are provided which, in a first embodiment, contain a plurality of multiphase capsules in which first and second therapeutic agents are contained in separate phases within said multiphase capsules, and are disposed to deliver said first and therapeutic agents by at least two different delivery mechanisms. | 2011-02-03 |
| 20110027354 | ANTI-PARKINSONIAN COMPOUNDS - The present application describes a composition comprising a neuroprotective effective amount of N-methyl-N-propynyl-2-phenylethylamine (MPPE). | 2011-02-03 |
| 20110027355 | HIGH-FLUIDITY AND NON-CAKING PULVERULENT CRYSTALLINE MALTITOL COMPOSITION - A pulverulent crystalline maltitol composition, is characterized in that it has a laser volume mean diameter between 10 and 150 μm; in that it has a maltitol content between 80 and 99.9% by weight; in that at least 50% by weight of its particles flow through a sieve having a cut-off threshold of 2000 μm according to a test A1; in that at least 35% by weight of its particles flow through a sieve having a cut-off threshold of 2000 μm according to a test A2; and in that it includes from 0.1 to 20% by weight of at least one water-insoluble anti-caking agent, the anti-caking agent having a hygroscopicity, determined according to the test B, between 2.5 and 25%. This composition is not subject to caking, and finds applications in the food and pharmaceutical fields. | 2011-02-03 |
| 20110027356 | Combination of Oral Medicaments Bonded by a Wrapping - Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel. | 2011-02-03 |
| 20110027357 | Compositions and methods for timed release of water-soluble nutritional supplements - A timed or controlled release composition is provided where a plurality of active pellets is layered with a controlled release layer whereby the single functional component of the controlled release layer is shellac and/or a shellac based material. | 2011-02-03 |
| 20110027358 | VALSARTAN TABLET FORMULATIONS - The present invention relates to a pharmaceutical tablet composition comprising an effective amount of valsartan. The tablet is prepared by wet granulation and exhibits satisfactory disintegration properties. The invention also relates to a process for preparation of a pharmaceutical tablet composition comprising an effective amount of valsartan wherein the process involves a wet granulation step. | 2011-02-03 |
| 20110027359 | Novel Pharmaceutical Compositions Comprising Levetiracetam - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 2011-02-03 |
| 20110027360 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 2011-02-03 |
| 20110027361 | EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE - The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same. | 2011-02-03 |
| 20110027362 | TABLET HAVING IMPROVED ELUTION PROPERTIES - The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. | 2011-02-03 |
| 20110027363 | Nouvelle forme d'administration de proteines osteogeniques - Osteogenic compositions are formed from a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, the coprecipitate being in divided form. A process for preparing the coprecipitate in divided form contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products, kits and medical devices comprising the coprecipitate. | 2011-02-03 |
| 20110027364 | BIOACTIVE AND RESORBABLE SOYBEAN-BASED BIOMATERIALS - A method of producing a soybean-based biomaterial which is suitable for use in a biomedical product, the method comprising: defatting soy flour; either prior to or at the same time as, performing a solvent extraction; to produce a biomaterial comprising variable levels of soy proteins, carbohydrates and isoflavones. The resulting biomaterials have a range of biomedical uses and are particularly desirable because of their isoflavone content. Examples of biomedical products containing the biomaterials include wound dressings; scaffolds for tissue engineering; fillers or implants for use in surgery; temporary barriers for use in dental or surgical procedures or to prevent post-surgical tissue adherence; carriers for the delivery of drugs, bioactive peptides or plasmids; anti-inflammatory agents; coatings for wound dressings or for dental, medical, surgical or veterinary devices or implants; and compositions for soothing skin or gum irritation. | 2011-02-03 |
| 20110027365 | Patch Formulation For External Use - A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate. | 2011-02-03 |
| 20110027366 | SKIN EQUIVALENT CULTURE - Disclosed is a method of preparing a collagenous construct comprising casting a support matrix comprising fibrin and viable collagen-producing cells onto a support material, wherein said cells include human dermal fibroblasts, incubating in situ said support matrix in a collagen-inducing medium thereby, inducing or enhancing collagen production by said cells to form a collagenous construct, and degrading said fibrin, and rendering said collagenous construct free of said viable collagen-producing cells. | 2011-02-03 |
| 20110027367 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 2011-02-03 |
| 20110027368 | POLYMERIC COMPOSITIONS COMPRISING THERAPEUTIC AGENTS IN CRYSTALLINE PHASES, AND METHODS OF FORMING THE SAME - The present invention relates to a drug-containing polymeric composition comprising at least one therapeutic agent encapsulated in at least one biocompatible polymer, wherein at least a portion of the therapeutic agent in this polymeric composition is crystalline. The at least one biocompatible polymer may form a substantially continuous polymeric matrix with the at least one therapeutic agent encapsulated therein. Alternatively, the at least one biocompatible polymer may form polymeric particles with the at least one therapeutic agent encapsulated therein. | 2011-02-03 |
| 20110027369 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS - The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C | 2011-02-03 |
| 20110027370 | Sustained Drug Release Composition - The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent. | 2011-02-03 |
| 20110027371 | Nanoparticulate statin formulations and novel statin combinations - The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught. | 2011-02-03 |
| 20110027372 | MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 2011-02-03 |
| 20110027373 | METHODS AND COMPOSITIONS FOR MODULATING SIALIC ACID PRODUCTION AND TREATING HEREDITARY INCLUSION BODY MYOPATHY - According to certain embodiments of the present invention, methods for modulating the production of sialic acid in a system are provided, which comprise providing the system with a wild-type GNE-encoding nucleic acid sequence. According to such embodiments, the system may comprise a cell, muscular tissue, or other desirable targets. Similarly, the present invention encompasses methods for producing wild-type GNE in a system that comprises a mutated endogenous GNE-encoding sequence. In other words, the present invention includes providing, for example, a cell or muscular tissue that harbors a mutated (defective) GNE-encoding sequence with a functional wild-type GNE encoding sequence. | 2011-02-03 |
| 20110027374 | CAPECITABINE RAPIDLY DISINTEGRATING TABLETS - There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400μ), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Ludiflash® or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. | 2011-02-03 |
| 20110027375 | USE OF LANTHANIDE-BASED NANOPARTICLES AS RADIOSENSITIZING AGENTS - The invention relates to the use of nanoparticles with dimensions comprised between 1 and 50 nm, at least one portion of which consists of at least one oxide and/or one oxohydroxide of at least one lanthanide, said nanoparticles:
| 2011-02-03 |
| 20110027376 | Hollow Multi-Layered Microspheres for Delivery of Hydrophilic Active Compounds - The present invention refers to a method of synthesizing a multi-walled microsphere comprising at least one hydrophilic active compound as well as to a multi-walled microsphere obtained by the method of the present invention. The present invention further refers pharmaceutical compositions including multi-walled microspheres of the present invention. | 2011-02-03 |
| 20110027377 | IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM - A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from above about 20% to 50% by weight of the composition, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 85% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharma-ceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipient (ii) to said second excipient (iii) is in a range from 1:1 to 5:1. | 2011-02-03 |
| 20110027378 | PROCESS OF MAKING FLOWABLE HEMOSTATIC COMPOSITIONS AND DEVICES CONTAINING SUCH COMPOSITIONS - The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which is substantially homogenously dispersed throughout the continuous liquid phase, methods for making such compositions, medical devices that contain sterilized hemostatic compositions disposed therein and methods of making such devices. | 2011-02-03 |
| 20110027379 | Oligo-Ethylene Glycol-Based Polymer Compositions and Methods of Use - The invention provides biodegradable PEAs, PEURs and PEUs that are synthesized by solution polycondensation to include α-amino acids and oligo-ethylene ether segments in the polymer backbone. The polymers can be obtained by substituting oligo-ethylene glycol (OEG) for aliphatic di-acid and diols during their fabrication. Also provided are compositions in which bioactive agents are dispersed in the polymers. The compositions biodegrade by enzymatic action to release incorporated bioactive agents and oligo-ethylene glycol segments, which are fully biodegradable at a molecular weight less than 400 Da. Due to their comparatively rapid surface enzymatic hydrolysis, the compositions can be used to deliver bioactive agents in a controlled manner within a relatively rapid delivery time, such as about 18 to 24 hours. | 2011-02-03 |
| 20110027380 | CARBON DIOXIDE REMOVAL FROM WHOLE BLOOD BY PHOTOLYTIC ACTIVATION - Apparatus and methods for removing carbon dioxide from whole blood. Hydrogen ions are generated from water in the blood, resulting in the formation and release of carbon dioxide from the blood. | 2011-02-03 |
| 20110027381 | TREATMENT OF OSTEOPOROSIS - The present invention relates to a combination for the treatment of osteoporosis and/or the prophylaxis and treatment of bone fractures, said combination comprising collagen, an additional peptide, a calcium-containing substance and a wetting agent with a terminally functionalized oligolactone. The invention also relates to artificial bones and implants produced by the combination and to the use of said combination for fixing implants and treating osteoporosis and/or the prophylaxis and treatment of bone fractures. The invention further relates to a method for producing artificial bones and implants. | 2011-02-03 |
| 20110027382 | Solubilized benzoyl peroxyde acne - The invention relates to a novel solubilized benzoyl peroxide topical formulation for the treatment of acne comprising: benzoyl peroxide, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the benzoyl peroxide is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation. | 2011-02-03 |
| 20110027383 | METHOD AND COMPOSITION FOR WASHING POULTRY DURING PROCESSING - The present invention relates to compositions including peroxyacetic acid and peroxyoctanoic acid and methods for reducing microbial contamination on poultry. The methods include the step of applying a mixed peroxycarboxylic acid composition to poultry. | 2011-02-03 |
| 20110027384 | PHOTOSENSITISING COMPOSITION AND ITS USES - The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms. | 2011-02-03 |
| 20110027385 | NANO-PARTICLE DISPERSIONS - A process for the production of an aqueous dispersion of metal nano particles comprising palladium is provided. The process comprises the admixture of a water soluble organic polymer, a palladium salt and a first reducing agent to an aqueous liquid. The first reducing agent is a metal-containing polymer which has reducing properties or a saccharide which has reducing properties. The nano particles can include a second metal. The dispersions can be used as catalysts for electroless plating, to produce heterogeneous catalysts and in the production of anti-microbial devices and compositions. | 2011-02-03 |
| 20110027386 | Antimicrobial zeolite and antimicrobial composition - The present invention relates to antimicrobial zeolite which comprises zeolite wherein a hardly soluble zinc salt is formed within fine pores present therein and an antimicrobial composition which comprises the foregoing antimicrobial zeolite in an amount ranging from 0.05 to 80% by mass. The antimicrobial zeolite according to the present invention can widely be applied, without causing any color change, even to the goods which undergo color changes with the elapse of time when the conventional antimicrobial zeolite is added. | 2011-02-03 |
| 20110027387 | Nutritional supplement for use with poultry and livestock and method of using - A first composition including copper sulfate, citric acid, ammonium carbonate, propionic acid, | 2011-02-03 |
| 20110027388 | Cobalt Hexammine as a Potential Therapeutic Against HIV and/or Ebola Virus - Hexaamminecobalt(III) chloride, also called Cohex, reduces the extent of viral infection, including difficult to treat infections caused by Ebola virus and HIV. Disclosed are methods for treating a viral infection, comprising administering to a patient a cobalt(III) hexammine compound in an amount effective to reduce an extent of a viral infection. Also disclosed are kits for delivery of a cobalt(III) hexammine compound by injection. | 2011-02-03 |
| 20110027389 | Low Viscosity Liquid Polymeric Delivery System - Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a biodegradable liquid polymer implant are provided. | 2011-02-03 |
| 20110027390 | Methods for Reducing Cisplatin Nephrotoxicity - The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as cisplatin. The invention provides compositions comprising a substituted cyclodextrin, cisplatin and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the cisplatin. | 2011-02-03 |
| 20110027391 | LIQUID NUCLEOTIDES/NUCLEOSIDES-CONTAINING PRODUCT - The invention pertains to a liquid composition for preventing and/or treating memory decline and/or cognitive dysfunction, Alzheimer's, Parkinson's and/or dementia, said composition comprising: (i) at least 50 mg nucleoside and/or nucleotide per 100 ml; (ii) between 0.2 and 10 grams protein per 100 ml; (iii) between 0.05 and 3 wt. % of 5 thickener, based on total weight of the composition. The thickener is preferably selected from the group consisting of cellulose, xanthan gum, gellan gum, alginate, guar gum, locust bean gum, gum karaya, gum tragacanth, carrageenan, and mixtures thereof. The composition preferably has a loss factor tan δ between 0.1 and 100, as measured at any strain in the range of 1 100% at 0.1 Hz and 20° C. It is particularly found that a thickener selected from the group consisting of gellan gum, xanthan gum and cellulose greatly reduces sedimentation. | 2011-02-03 |
| 20110027392 | Peracetic Acid in an Anhydrous Sterilant Delivery System - Method and system for forming an anhydrous sterilant. In one embodiment, anhydrous peracetic acid is combined with carbon dioxide, wherein the carbon dioxide is in one of a liquid, solid, and supercritical state. | 2011-02-03 |
| 20110027393 | HUMAN DIABETES SUSCEPTIBILITY EEFSEC GENE - The present invention relates to a diagnostic method of determining whether a subject, preferably an obese subject, is at risk of developing type 2 diabetes or diabetic complications, which method comprises detecting the presence of an alteration in the EEFSEC gene locus in a biological sample of said subject. | 2011-02-03 |
| 20110027394 | Cross-Linked Biopolymers, Related Compounds and Methods of Use - The present invention provides stabilized oil-in-water emulsions with an extended range of chemical, thermal and/or mechanical stabilities, and method(s) for their preparation. Such preparations provide an environmentally-protective biopolymer component exhibiting improved adherence to the dispersed phase, reducing or eliminating dissociation therefrom under such conditions, for use in the context of a range of food, pharmaceutical, personal care, health care, cosmetic and other end-use applications. | 2011-02-03 |
| 20110027395 | Liquid animal repellant containing oils of black paper and capsicum - The present invention provides a novel liquid animal repellant composition which is environmentally safe, non-toxic, long-lasting and efficacious against a wide of animals such as dogs, cats, raccoons, skunks, mice, rats, squirrels, chipmunks, deer, etc. | 2011-02-03 |
| 20110027396 | NOVEL MILK THISTLE EXTRACT, METHOD FOR THE PRODUCTION, AND USE - A method for preparing a milk thistle fruit extract, in particular a flavanolignan preparation, has an increased release rate and improved absorbability. A pharmaceutical preparation contains the extract and is used, in particular for the treatment and prevention of liver diseases. | 2011-02-03 |
| 20110027397 | METHODS OF TREATING AUTISM SPECTRUM DISORDERS AND COMPOSITIONS FOR SAME - Disclosed are compositions that inhibit brain blood vessel leakage, compositions for treating autism spectrum disorders, methods of treating autism spectrum disorders, and methods of screening for an autism spectrum disorder. | 2011-02-03 |
| 20110027398 | METHODS OF MAKING OLIVE JUICE EXTRACTS CONTAINING REDUCED SOLIDS - Solids, including fibers can be easily removed from olive juice by mixing the olive juice with a water-miscible solvent to form two phases and separating the phases. Preferably the solvent is ethanol. | 2011-02-03 |
| 20110027399 | Antiviral Agent and Antiviral Composition - An antiviral agent is provided which has an excellent effect on a non-enveloped virus and which is highly safe to the human body, and an antiviral composition which comprises the antiviral agent and which is useful for disinfection of the virus or prevention of infection of the virus. The antiviral agent comprises as an active ingredient an extract from a plant of the genus | 2011-02-03 |
| 20110027400 | POWDER PRESS FOR THE MANUFACTURE OF A METAL POWDER COMPACT - A powder press for producing a metal powder compact comprises an upper punch arrangement and a lower punch arrangement ( | 2011-02-03 |
| 20110027401 | FOOD EXTRUDER - A food extruder including a barrel provided at one end with an outlet from which the food substance can be extruded, a rotatable screw positioned within the barrel that is capable of being rotated and moved longitudinally within the barrel, a handle member at a top end of the rotatable screw for manual engagement, and a rod member protruding from an upper portion of the handle member for insertion into a drill chuck or other motorized means. The rod member, in a preferred embodiment, has a hexagonal cross section, which facilitates insertion and securement within a drill chuck or a receptacle for other motorized means, which may be used to turn the rotatable screw, rather than having to turn it manually. Additionally, a hand grip member may be attached to the barrel member at a generally right angle thereto, so that a user may grip the hand grip while using the drill or other motorized means to turn the rotatable screw, in order to prevent the entire extruder from rotating. | 2011-02-03 |
| 20110027402 | Process for Making Angstrom Scale and High Aspect Functional Platelets - A process for making functional or decorative flakes or platelets economically and at high production rates comprises applying a multi-layer sandwich of vapor deposited metal and release coats in alternating layers to a rotating chilled drum or suitable carrier medium contained in a vapor deposition chamber. The alternating metallized layers are applied by vapor deposition and the intervening release layers are preferably solvent soluble thermoplastic polymeric materials applied by vapor deposition sources contained in the vapor deposition chamber. The multi-layer sandwich built up in the vacuum chamber is removed from the drum or carrier and treated with a suitable organic solvent to dissolve the release coating from the metal in a stripping process that leaves the metal flakes essentially release coat free. The solvent and dissolved release material are then removed by centrifuging to produce a cake of concentrated flakes which can be air milled and let down in a preferred vehicle and further sized and homogenized for final use in inks, paints or coatings. In one embodiment the finished flakes comprise single-layer thin metal or metal alloy flakes or flakes of inorganic materials, and in another embodiment flakes are coated on both sides with protective polymeric coatings that were applied from suitable vacuum deposition sources or the like contained in the vapor deposition chamber. | 2011-02-03 |
| 20110027403 | HEAD ASSEMBLY FOR USE IN A ROTARY HEAD EXTRUDER FOR EXTRUDING A FOOD PRODUCT - A head assembly ( | 2011-02-03 |
| 20110027404 | MULTI-TUBE EXTRUSION APPARATUS AND METHOD - A method and apparatus for producing a plurality of bi-oriented, heat-shrinkable thermoplastic tubular films is disclosed. Thermoplastic resin is extruded through a plurality of annular dies to form a plurality of molten plastic tubes. The tubes are cooled and solidified and sent through a plurality of pinch rollers to stretch the tubes simultaneously in a machine and transverse direction, creating a plurality of tubular films. The films are cooled and heated, and then relaxed simultaneously in a machine and transverse direction. Winding rollers then wind up the finished tubular films. | 2011-02-03 |
| 20110027405 | Corner-Consolidating Inflatable Method for Manufacturing Composite Structures - An inflatable compaction tool for consolidating a composite material inside a faceted hollow or tubular mold for a composite part is made from an elastic material. The compaction tool includes relatively flat wall segments conjoined by corner segments that define a sealed chamber. The wall segments curve away from the mold surface toward the midpoint of each wall segment, so that as a pressurized fluid is introduced into the compaction tool, a component of the force exerted on the tool interior surface is transmitted through the wall segments toward the corner segments. Thus, during initial inflation, the corner segments are forced toward the corner regions of the mold before the wall segments contact the composite material, firmly compressing the composite material into the corner regions of the mold before the friction of the wall segments against the composite material inhibits expansion of the corner segments into the mold corner regions. | 2011-02-03 |
| 20110027406 | DIE FOR MOLDING CERAMIC HONEYCOMB STRUCTURE - A die comprising molding grooves arranged in a lattice pattern and moldable-material-supplying holes communicating with the molding grooves for molding a ceramic honeycomb structure, the molding grooves having width of 0.05-0.5 mm, the moldable-material-supplying holes being arranged in every intersecting portions of the molding grooves, or in every other intersecting portions of the molding grooves in a checkerboard pattern, and an average distance between the centers of the intersecting portions of the molding grooves, at which the moldable-material-supplying holes are arranged, and the center axes of the moldable-material-supplying holes being 10-100 μm. | 2011-02-03 |
| 20110027407 | PROFILE CONTROL UTILIZING A RECESSED IMPRINT TEMPLATE - An imprint template is provided with a shallower field bordering the patterned region. The shallower field can be formed with additional lithography/etch steps after (or before) the formation of the features in the patterned region. The template is used to establish a thin film pattern with a field thickness that is shallower than the pattern. A shallower field bordering the patterned region alleviates sidewall re-deposition during ion mill. In a planarization/etch-back process, a thinner field helps to achieve a flat top surface by compensating for the thickness variation caused by different filling ratios. Fabrication of the recessed field template comprises a multi-step patterning process. The initial patterns are formed using a convention fabrication process. A second patterning step is used to reduce the height of the field region, which can be applied by coating the “half-finished” template with a suitable resist pattern and patterning the resist using a second lithography step that is aligned to the original pattern. Template material in the field region is then etched with the resist as a mask, forming a template with a recessed field region after the remaining resist is removed. It should be appreciated that the order of these etch steps can be reversed to obtain the same result. | 2011-02-03 |
| 20110027408 | SEAMLESS MOLD MANUFACTURING METHOD - A seamless mold manufacturing method of the invention is a seamless mold manufacturing method having the steps of forming a thermal reaction type resist layer on a sleeve-shaped mold, and exposing using a laser and developing the thermal reaction type resist layer and thereby forming a fine mold pattern, and is characterized in that the thermal reaction type resist layer is comprised of a thermal reaction type resist having a property of reacting in predetermined light intensity or more in a light intensity distribution in a spot diameter of the laser. | 2011-02-03 |
| 20110027409 | RAPID CHANGEOVER MECHANISM FOR BOTTOM PORTIONS - An apparatus for moulding plastic preforms into plastic containers may include at least one blow moulding station having a cavity. Within the cavity, the plastic preforms may be expanded into plastic containers. The blowing station has a bottom portion which delimits the cavity. The bottom portion is detachably disposed on a carrier by a fastening mechanism. The fastening mechanism has at least one pin-like body disposed on a first fastening element. The pin-like body engages in a condition in which the bottom portion is fastened to the carrier in a groove which is provided in a second fastening element. The pin-like body is displaceable relative to the carrier in the groove for fastening the bottom portion, and the groove is designed in such a way that an end section of the pin-like body may pass through the groove in a first section of the groove and cannot pass through the groove in a second section of the groove. | 2011-02-03 |
| 20110027410 | Back-Up Device for Use in a Melt Distribution Apparatus of an Injection Molding System - Disclosed, amongst other things, is a back-up device that is configured to provide a structural support, in use, between a manifold and a housing member within a melt distribution apparatus of an injection molding system. The back-up device is associated, in use, with a valve-gate apparatus within a nozzle drop. The back-up device includes a cold-side member formed from a first material and a hot-side member formed from a second material. The first material is more thermally conductive than the second material. The cold-side member is configured to be thermally connectable, in use, with the housing member and the hot-side member. The hot-side member is configured to be thermally connectable, in use, with the manifold and the cold-side member. The hot-side member is also configured to prevent the cold-side member from directly contacting the manifold. | 2011-02-03 |
| 20110027411 | Decompression sprue bush and decompression machine nozzle - The present invention concerns a transfer element ( | 2011-02-03 |
| 20110027412 | Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health - A composition for promoting gastrointestinal and/or cardiovascular health comprising a gelling dietary fiber and a non-gelling dietary fiber in a weight ratio of from about 5:1 to about 1:2.5; a coating component and a wetting component in a weight ratio of from about 20:1 to about 1:1; wherein a weight ratio of coating component plus wetting component to said gelling dietary fiber or said non-gelling dietary fiber is from about 25:1 to about 1:5 is disclosed. Also disclosed herein is a composition for promoting gastrointestinal and/or cardiovascular health comprising a gelling dietary fiber; a non-gelling dietary fiber; and an amount of a coating component sufficient to coat the particles of the gelling dietary fiber, such that the water-absorbing ability is reduced and the organoleptic properties of the composition are improved. Methods of promoting gastrointestinal and/or cardiovascular health are also included. | 2011-02-03 |
